Who owns Lyell Immunopharma, Inc. (LYEL)? Elite investor 13F holders
2 tracked elite investors reported holding Lyell Immunopharma, Inc as of 2026-06-30, including Alphabet, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Alphabet | LYELL IMMUNOPHARMA INC | SHARE | 2026-06-30 | 2026-08-07 00:00:00 | 4120247.00 USD | 293256.000000 | Shares | hold | Original filing |
| Renaissance Technologies LLC | LYELL IMMUNOPHARMA INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1829169.00 USD | 130190.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.